Aripiprazole Carlat Reports | Carlat Publishing

Clinical Update

Medications to Rapidly Treat Psychotic Agitation

From The Carlat Hospital Psychiatry Report, Agitation

Topics: | | | | | | | | | | | | | | | | | | Agitation Antipsychotics Aripiprazole Benzodiazepines Chlorpromazine De-escalation Diphenhydramine Droperidol Emergency Haloperidol Hydroxyzine olanzapine Pharmacotherapy Promethazine Psychosis Quetiapine Risperidone Violence Ziprasidone

If you work in an emergency department (ED) or psychiatric inpatient unit, you’ve encountered agitated and even violent patients. We can help many patients settle down by listening empathically, validating their emotions, and offering oral medications, but even with our best efforts, these interventions do not always work. Medications help reduce agit

Clinical Update

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

From The Carlat Hospital Psychiatry Report, Metabolic Side Effects

Many psychiatric medications cause weight gain, including mood stabilizers, antidepressants, and especially antipsychotics. Most weight gain secondary to antipsychotic use occurs in the first 6 months of therapy, so it’s important to monitor weight closely and intervene early in a patient’s treatment. We counsel patients at every visit about healthy

Expert Q&A

Weight Gain and Metabolic Side Effects

From The Carlat Hospital Psychiatry Report, Metabolic Side Effects

CHPR: Dr. Marder, can you please tell us about your work? Dr. Marder: Sure. My work has focused on pharmacologic and nonpharmacologic approaches to improving the outcomes of serious mental illnesses, particularly schizophrenia. I’m very interested in ways to combine psychosocial interventions with pharmacological approaches and to reduce adverse side

Research Update

Hyperprolactinemia: Effective Treatment With Aripiprazole

From The Carlat Hospital Psychiatry Report, Capacity Assessments

Topics: Aripiprazole | Prolactin

Review of: Zheng W et al, General Psychiatry 2019;32(5):e100091 Antipsychotic-induced hyperprolactinemia is a common adverse reaction contributing to treatment non-adherence. Male patients are embarrassed by the resulting breast enlargement, and female patients experience amenorrhea, infertility, and reduced bone density. We can bring prolactin level

Expert Q&A

Pharmacotherapy for Autism Spectrum Disorder

From The Carlat Child Psychiatry Report, Autism in Children and Adolescents

CCPR: Welcome, Dr. Krause. Tell us a little bit about the recent paper you coauthored called Pharmacologic Management of Autism Spectrum Disorder: A Review of Seven Studies (Kothadia RJ et al, Current Psychiatry 2021;20(1):33–38). Dr. Krause: Our study was a review of reviews. The aim was to see if we could find any new insights into medication treat

Research Update

Weight Gain From Aripiprazole Same as Risperidone

From The Carlat Child Psychiatry Report, Autism in Children and Adolescents

Review of: Schoemakers RJ et al, J Child Adolesc Psychopharm 2019;29(3):192–196 Many providers prefer aripiprazole over risperidone for young patients due to observed lower incidence of weight gain. This is supported in studies with follow-up of less than 3 months. However, does aripiprazole fare better with long-term use? Researchers reviewed r

Expert Q&A

The Schizophrenia-OCD Overlap

From The Carlat Psychiatry Report, Mood Disorders

TCPR: What is schizo-obsessive disorder?Dr. Poyurovsky: Schizo-obsessive disorder (schizo-OCD) is not a DSM diagnosis. The term is used to refer to patients with schizophrenic disorders that have comorbid features of OCD. We see these obsessive-compulsive symptoms in schizophrenia more often than would be expected by chance. About one in four patients h

Research Update

Antipsychotic Use Associated With Increased Risk of Mortality

From The Carlat Psychiatry Report, Stopping Psych Meds Part 2

Topics: Antidepressant Augmentation | Antipsychotics | Aripiprazole | Mortality

REVIEW OF: Gerhard T et al, PLoS One 2020;15(9):e0239206 TYPE OF STUDY: Population-based comparator cohort study We know that atypical antipsychotics increase mortality in elderly patients with dementia—the FDA has long required a black box warning to that effect. But are these medications also dangerous when prescribed to younger people with de

Research Update

Mood Stabilizers: What You Don’t Know Can Hurt Them

From The Carlat Psychiatry Report, Mood and Menopause

Review of: Bai Y et al, J Clin Psychopharmacol 2020;40(2):167–179 STUDY TYPE: Combined meta-analysis and literature review of placebo-controlled trials Medication adherence is an ongoing struggle in bipolar disorder, and it’s compounded by the fact that our patients often don’t advertise their non-adherence. While numbers vary, reviews general

Clinical Update

How to Choose an Antipsychotic in Schizophrenia

From The Carlat Psychiatry Report, Psychopharmacology Algorithms

It’s been over a decade since the CATIE trial changed the way we look at antipsychotic drugs. Since then, the number of second-generation antipsychotics has about doubled, and the number of clinical trials has risen even more. Antipsychotics are not all the same, though, and when it comes to schizophrenia, a few stand out in ways that can help you fin